Reve Technologies, Inc. (BSSP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2014 | 57.09 Thousand USD | 2304.97% |
| 2013 | 2374.00 USD | 511.86% |
| 2012 | 388.00 USD | -90.69% |
| 2011 | 4167.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2015 Q3 | 10.95 Thousand USD | -47.86% |
| 2015 Q1 | 37.62 Thousand USD | -34.11% |
| 2015 Q2 | 21 Thousand USD | -44.17% |
| 2014 Q2 | 3212.00 USD | -23.87% |
| 2014 Q4 | 57.09 Thousand USD | 2335.75% |
| 2014 Q3 | 2344.00 USD | -27.02% |
| 2014 Q1 | 4219.00 USD | 77.72% |
| 2014 FY | 57.09 Thousand USD | 2304.97% |
| 2013 Q3 | 8421.00 USD | 110.37% |
| 2013 FY | 2374.00 USD | 511.86% |
| 2013 Q4 | 2374.00 USD | -71.81% |
| 2013 Q2 | 4003.00 USD | -20.98% |
| 2013 Q1 | 5066.00 USD | 1205.67% |
| 2012 FY | 388.00 USD | -90.69% |
| 2012 Q1 | 654.00 USD | -84.31% |
| 2012 Q2 | 1861.00 USD | 184.56% |
| 2012 Q3 | 1197.00 USD | -35.68% |
| 2012 Q4 | 388.00 USD | -67.59% |
| 2011 Q4 | 4167.00 USD | -36.63% |
| 2011 Q3 | 6576.00 USD | 8.64% |
| 2011 Q2 | 6053.00 USD | 0.0% |
| 2011 FY | 4167.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -2371.602% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 97.084% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.459% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 89.659% |
| Rebus Holdings, Inc. | 5000.00 USD | -1041.88% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.956% |
| Qrons Inc. | 420.00 USD | -13493.81% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 92.591% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.796% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 88.119% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.522% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.853% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.209% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 25.225% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.947% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 96.013% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 21.103% |
| Mesoblast Limited | 667.9 Million USD | 99.991% |
| Marizyme, Inc. | 22.01 Million USD | 99.741% |
| Genus plc | 1.02 Billion USD | 99.994% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 95.797% |
| Pharming Group N.V. | 462.85 Million USD | 99.988% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 98.277% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 88.559% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 90.894% |
| ContraFect Corporation | 20.67 Million USD | 99.724% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 85.374% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 85.061% |
| IMV Inc. | 31.33 Million USD | 99.818% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 98.623% |
| MultiCell Technologies, Inc. | 126.22 USD | -45133.719% |
| ONE Bio Corp. | 70.08 Million USD | 99.919% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 93.924% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.956% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 86.775% |
| Q BioMed Inc. | 3.51 Million USD | 98.376% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.838% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 78.148% |
| Biomind Labs Inc. | 73.81 Thousand USD | 22.657% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.987% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 96.059% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.81% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 97.921% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 91.695% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 97.807% |
| GB Sciences, Inc. | 103.44 Thousand USD | 44.806% |
| Alpha Cognition Inc. | 2.45 Million USD | 97.672% |
| HST Global, Inc. | 1526.00 USD | -3641.415% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 94.221% |
| Halberd Corporation | 10.13 Thousand USD | -463.557% |
| Enzolytics Inc. | 361.7 Million USD | 99.984% |
| Agentix Corp. | 261.39 Thousand USD | 78.158% |
| Resverlogix Corp. | 8.11 Million USD | 99.296% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 96.96% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.88% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 91.074% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -150.621% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.362% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.226% |
| Zenith Capital Corp. | 7410.00 USD | -670.499% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 184.00 USD | -30929.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 82.258% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 78.155% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 93.847% |
| Kadimastem Ltd | 2.3 Million USD | 97.522% |
| Helix BioMedix, Inc. | 3.02 Million USD | 98.113% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.892% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.608% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| LadRx Corporation | 2.3 Million USD | 97.526% |
| Cell Source, Inc. | 195.17 Thousand USD | 70.747% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 83.854% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 83.854% |
| NovAccess Global Inc. | 62.24 Thousand USD | 8.28% |
| Affymax, Inc. | 7.44 Million USD | 99.233% |
| Itoco Inc. | 1.4 Million USD | 95.922% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 40.314% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 46.138% |
| Mobile Lads Corp. | 52.00 USD | -109696.154% |
| CytoDyn Inc. | 11.13 Million USD | 99.487% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 60.066% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -219.318% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 85.189% |
| SYBLEU INC | 330.46 Thousand USD | 82.723% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 86.055% |
| International Stem Cell Corporation | 5.39 Million USD | 98.941% |
| Bioxytran, Inc. | 137.63 Thousand USD | 58.519% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.619% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.656% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 27.729% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 93.397% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.24% |
| Neutra Corp. | 2851.00 USD | -1902.596% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.824% |
| PureTech Health plc | 693.97 Million USD | 99.992% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.293% |
| IXICO plc | 15.84 Million USD | 99.64% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.311% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.945% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.983% |